10/20/2016 03:00 p.m. - 06:00 p.m.
Japan and Pharmaceutical + Medical Device
5-1, Marunouchi 1-Chome
Rika Saeki, Kyoko Sato, Yemi Tépé, Louise C. Stoupe, and Aramide O. Fields
Yemi Tépé, Louise C. Stoupe, Rika Saeki, Aramide O. Fields, and Kyoko Sato
This seminar will focus on the new legal and economic developments trends and challenges in the region in the following two important areas driving global business:
Lessons from The Pharmaceutical Industry: Dealing With Change
The pharmaceutical industry has been undergoing dramatic transformations to deal with changes in the population while also adapting to the integration of digital technology. In this seminar, we will have two professionals from the pharmaceutical industry discuss the transition from traditional technology to the electronic era. They will also provide an exciting opportunity to learn about how the changing population is changing the pharmaceutical industry. This is one of the fastest growing industries globally and the way that it is expanding into areas beyond its traditional borders such as digital technology, provides useful lessons for professionals in all industries.
Brexit - Calm Before the Storm?
In the immediate aftermath of the 23 June Brexit vote, the doom and gloom predictions of the “Remain” campaigners appeared to have come true. On 24 June, the pound plunged dramatically against the US dollar and the euro. Volatility in the global markets had caused $2 trillion of losses. The International Monetary Fund and the credit rating agencies lowered their outlook for the UK which lost its prized AAA rating. However, recent data shows an apparent rebounding after the initial shock of the Brexit vote. The UK economy appears to be defying predictions of a recession as consumers are actively spending again, sales across various industry sectors are up and the world markets seem to be calm. But Japan’s recent message to the UK and the EU exposes this false sense of security and warns of the uncertainty, complexity and disruption to come.
©1996-2017 Morrison & Foerster LLP. All rights reserved.